# Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

> **NCT06123468** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 58 (actual)

## Conditions studied

- Esophagogastric Adenocarcinoma

## Interventions

- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06123468
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-17
- **Primary completion:** 2026-01-07
- **Final completion:** 2026-01-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06123468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06123468, "Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06123468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*